title: [Pharmacogenetic testing: utility in drug development and in routine clinical practice].
abstract: Pharmacogenetic tests can identify the role of genetic factors in the inter-individual variability of drug responsiveness. This variability can involve three systems, namely drug-metabolizing enzymes, transmembrane drug transporters, and drug effctor sites (receptors, enzymes, ion, channels, etc.). At present, pharmacogenetic testing is rarely used in clinical practice. A rapid survey of the four laboratories conducting such tests for Paris hospitals shows that about 750 tests were done during a 12-months period in 2004-2005, and that most focused on allelic variants of drug-metabolizing enzymes. Three other European laboratories perform between 25, and 7.000 tests per year. However, the number of pharmacogenetic tests is set to grow rapidely in the near future. The role of genetic factors in adverse drug reactions (ADR) has not yet been the subject of a systematic study. Drug-drug interactions that inhibit or induce certain enzyme activities are a major cause of adverse reactions, but they have not been exhaustively studied Pharmacogenetic and pharmacogenomic tools are increasingly used in the drug development process. This should result in the discovery of new therapeutic targets and in a better understanding of factors governing drug efficacy and tolerability. DNA samples are already collected systematically in many phase II and III clinical trials, and registration agencies such as the FDA are establishing guidelines for the submission of pharmacogenetic data on new drugs. These efforts, together with DNA samples collection during post-registration pharmacoepidemiological studies, should help to understand inter-individual variability in drug efficacy and tolerability. They may also result in the identification of new drug targets and will help to tailor therapy to the individual patient.
authors.affiliation: Service de pharmacologie, Hôpital Saint-Antoine AP-HP et Faculté de Médecine Pierre et Marie Curie Site Saint-Antoine, Université Paris 6, 27 rue de Chaligny 75012 Paris. patrice.jaillon@upmc.fr
authors.forename: Patrice
authors.initials: P
authors.lastname: Jaillon
mesh_terms: D015510:Clinical Medicine / Q000379:methods*; D002986:Clinical Trials as Topic; D004358:Drug Therapy; D005069:Evaluation Studies as Topic; D006801:Humans; D010597:Pharmacogenetics